Browse by UCL Departments and Centres
![[up]](/style/images/multi_up.png)
Up a levelGroup by: Author | Type
Number of items: 67.
A
Ainley, L;
Chavda, SJ;
Counsell, N;
Cheesman, S;
Newrick, F;
Horder, J;
Kyriakou, C;
... Yong, K; + view all
(2021)
DT‐PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation.
British Journal of Haematology
, 192
(3)
e73-e77.
10.1111/bjh.17248.
|
|
Arend, RC;
Monk, BJ;
Herzog, TJ;
Moore, KN;
Shapira-Frommer, R;
Ledermann, JA;
Tewari, KS;
... Penson, RT; + view all
(2021)
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.
Gynecologic Oncology
, 161
(2)
pp. 496-501.
10.1016/j.ygyno.2021.02.014.
|
|
Au, L;
Hatipoglu, E;
Robert de Massy, M;
Litchfield, K;
Beattie, G;
Rowan, A;
Schnidrig, D;
... TRACERx Renal Consortium; + view all
(2021)
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Cancer Cell
, 39
pp. 1497-1518.
10.1016/j.ccell.2021.10.001.
|
 |
B
|
Bachy, E;
Rufibach, K;
Parreira, J;
Launonen, A;
Nielsen, T;
Hackshaw, A;
(2021)
Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation.
Advances in Therapy
10.1007/s12325-021-01738-2.
(In press).
|
|
|
Baert, T;
Ferrero, A;
Sehouli, J;
O Donnell, DM;
González-Martín, A;
Joly, F;
Van der Velden, J;
... Ledermann, JA; + view all
(2021)
The systemic treatment of recurrent ovarian cancer revisited.
Annals of Oncology
, 32
(6)
pp. 710-725.
10.1016/j.annonc.2021.02.015.
|
|
Balestrini, S;
Koepp, MJ;
Gandhi, S;
Rickman, HM;
Yen Shin, G;
Houlihan, CF;
Anders-Cannon, J;
... Sisodiya, SM; + view all
(2021)
Clinical outcomes of COVID-19 in long-term care facilities for people with epilepsy.
Epilepsy & Behavior
, 115
, Article 107602. 10.1016/j.yebeh.2020.107602.
|
|
Bentham, R;
Litchfield, K;
Watkins, TBK;
Lim, EL;
Rosenthal, R;
Martinez-Ruiz, C;
Hiley, CT;
... McGranahan, N; + view all
(2021)
Using DNA sequencing data to quantify T cell fraction and therapy response.
Nature
, 597
pp. 555-560.
10.1038/s41586-021-03894-5.
|
|
Biasco, L;
Izotova, N;
Rivat, C;
Ghorashian, S;
Richardson, R;
Guvenel, A;
Hough, R;
... Amrolia, PJ; + view all
(2021)
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients.
Nature Cancer
, 2
pp. 629-64.
10.1038/s43018-021-00207-7.
|
C
|
Camilleri, M;
Sive, J;
Wilson, W;
Pang, G;
Jenner, R;
Phillips, E;
Popat, R;
... Yong, K; + view all
(2021)
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.
British Journal of Haematology
, 192
(1)
E14-E16.
10.1111/bjh.17168.
|
|
Camilleri, M;
Cuadrado, M;
Phillips, E;
Wilson, W;
Jenner, R;
Pang, G;
Kamora, S;
... Yong, K; + view all
(2021)
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
British Journal of Haematology
10.1111/bjh.17377.
(In press).
|
|
|
Clamp, AR;
Lorusso, D;
Oza, AM;
Aghajanian, C;
Oaknin, A;
Dean, A;
Colombo, N;
... Ledermann, JA; + view all
(2021)
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
International Journal of Gynecological Cancer
10.1136/ijgc-2020-002240.
(In press).
|
|
Clark, JJ;
Dwyer, D;
Pinwill, N;
Clark, P;
Johnson, P;
Hackshaw, A;
(2021)
The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis.
The Lancet Oncology
, 22
(1)
pp. 66-73.
10.1016/S1470-2045(20)30619-7.
|
|
Colombo, N;
Ledermann, JA;
(2021)
Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines.
Annals of Oncology
, 32
(10)
pp. 1300-1303.
10.1016/j.annonc.2021.07.004.
|
|
Concin, N;
Creutzberg, CL;
Vergote, I;
Cibula, D;
Mirza, MR;
Marnitz, S;
Ledermann, JA;
... Matias-Guiu, X; + view all
(2021)
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.
Virchows Archiv
, 478
pp. 153-190.
10.1007/s00428-020-03007-z.
|
|
Concin, N;
Matias-Guiu, X;
Vergote, I;
Cibula, D;
Mirza, MR;
Marnitz, S;
Ledermann, J;
... Creutzberg, CL; + view all
(2021)
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
Radiotherapy and Oncology
, 154
pp. 327-353.
10.1016/j.radonc.2020.11.018.
|
|
Concin, N;
Matias-Guiu, X;
Vergote, I;
Cibula, D;
Mirza, MR;
Marnitz, S;
Ledermann, J;
... Creutzberg, CL; + view all
(2021)
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
International Journal Of Gynecological Cancer
, 31
(1)
pp. 12-39.
10.1136/ijgc-2020-002230.
|
|
|
Cross, AJ;
Myles, J;
Greliak, P;
Hackshaw, A;
Halloran, S;
Benton, SC;
Addison, C;
... Raine, R; + view all
(2021)
Including a general practice endorsement letter with the testing kit in the Bowel Cancer Screening Programme: Results of a cluster randomised trial.
Journal of Medical Screening
10.1177/0969141321997480.
|
|
D
|
Dettorre, GM;
Dolly, S;
Loizidou, A;
Chester, J;
Jackson, A;
Mukherjee, U;
Zambelli, A;
... OnCovid study group; + view all
(2021)
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score.
Journal for ImmunoTherapy of Cancer
, 9
(3)
, Article e002277. 10.1136/jitc-2020-002277.
|
|
E
|
Elyashiv, O;
Wong, YNS;
Ledermann, JA;
(2021)
Frontline Maintenance Treatment for Ovarian Cancer.
Current Oncology Reports
, 23
(8)
, Article 97. 10.1007/s11912-021-01088-w.
|
|
|
Eyre, TA;
Wilson, W;
Kirkwood, AA;
Wolf, J;
Hildyard, C;
Plaschkes, H;
Griffith, J;
... Hatton, CSR; + view all
(2021)
Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP.
Blood Advances
, 5
(8)
pp. 2229-2236.
10.1182/bloodadvances.2021004286.
|
|
F
|
Fox, TA;
Kirkwood, AA;
Enfield, L;
O'Reilly, M;
Arulogun, S;
D'Sa, S;
O'Nions, J;
... Morris, EC; + view all
(2021)
Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
British Journal of Haematology
, 195
(5)
pp. 706-709.
10.1111/bjh.17836.
|
 |
G
|
Gleeson, M;
Counsell, N;
Cunningham, D;
Lawrie, A;
Clifton-Hadley, L;
Hawkes, E;
McMillan, A;
... Linch, D; + view all
(2021)
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.
British Journal of Haematology
, 192
(6)
pp. 1015-1019.
10.1111/bjh.16691.
|
H
|
Hackshaw, A;
Berg, CD;
(2021)
An efficient randomised trial design for multi-cancer screening blood tests: nested enhanced mortality outcomes of screening trial.
Lancet Oncology
, 22
(10)
pp. 1360-1362.
10.1016/S1470-2045(21)00204-7.
|
|
Hackshaw, A;
Cohen, SS;
Reichert, H;
Kansal, AR;
Chung, KC;
Ofman, JJ;
(2021)
Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK.
British Journal of Cancer
10.1038/s41416-021-01498-4.
(In press).
|
|
|
Hoskin, P;
Popova, B;
Schofield, O;
Brammer, C;
Robinson, M;
Brunt, AM;
Madhavan, K;
... Kirkwood, AA; + view all
(2021)
4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial.
The Lancet Oncology
, 22
(3)
pp. 332-340.
10.1016/S1470-2045(20)30686-0.
|
|
Hughes, J;
Gyertson, K;
Carballo, L;
Plant, H;
Sharman, M;
Ruane, K;
Mendoza-Naranjo, A;
... Fisher, P; + view all
(2021)
A feasibility trial of acupuncture in cancer patients undergoing radiotherapy treatment.
Complementary Therapies in Clinical Practice
, 43
, Article 101372. 10.1016/j.ctcp.2021.101372.
|
J
|
Javaid, F;
Pilotti, C;
Camilli, C;
Kallenberg, D;
Bahou, C;
Blackburn, J;
R. Baker, J;
... Chudasama, V; + view all
(2021)
Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target.
RSC Chemical Biology
, 2
(4)
pp. 1206-1220.
10.1039/d1cb00104c.
|
|
K
|
Kurtz, JE;
Gebski, V;
Sukhin, V;
Carey, M;
Kong, I;
Glasspool, RM;
Berek, JS;
... Friedlander, M; + view all
(2021)
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
Gynecologic Oncology
, 161
(2)
pp. 502-507.
10.1016/j.ygyno.2021.02.018.
|
|
Kwan, TT;
Oza, AM;
Tinker, A;
Ray-Coquard, I;
Oaknin, A;
Aghajanian, C;
Lorusso, D;
... Swisher, EM; + view all
(2021)
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib.
JAMA Oncology
10.1001/jamaoncol.2021.4664.
|
L
|
Lacas, B;
Carmel, A;
Landais, C;
Wong, SJ;
Licitra, L;
Tobias, JS;
Burtness, B;
... MACH-NC Collaborative Group; + view all
(2021)
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.
Radiotherapy and Oncology
, 156
pp. 281-293.
10.1016/j.radonc.2021.01.013.
|
|
Laszlo, HE;
Seward, E;
Ayling, RM;
Lake, J;
Malhi, A;
Stephens, C;
Pritchard-Jones, K;
... Machesney, M; + view all
(2021)
Faecal immunochemical test for patients with 'high-risk' bowel symptoms: a large prospective cohort study and updated literature review.
British Journal of Cancer
10.1038/s41416-021-01653-x.
(In press).
|
|
|
Leary, A;
Tan, D;
Ledermann, J;
(2021)
Immune checkpoint inhibitors in ovarian cancer: where do we stand?
Therapeutic Advances in Medical Oncology
, 13
10.1177/17588359211039899.
|
|
|
Lechner, M;
Liu, J;
Counsell, N;
Ta, NH;
Rocke, J;
Anmolsingh, R;
Eynon-Lewis, N;
... Philpott, C; + view all
(2021)
Course of symptoms for loss of sense of smell and taste over time in one thousand forty-one healthcare workers during the Covid-19 pandemic: Our experience.
Clinical Otolaryngology
, 46
(2)
pp. 451-457.
10.1111/coa.13683.
|
|
Ledermann, JA;
Zurawski, B;
Raspagliesi, F;
De Giorgi, U;
Arranz Arija, J;
Romeo Marin, M;
Lisyanskaya, A;
... Sehouli, J; + view all
(2021)
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study.
ESMO Open
, 7
(1)
, Article 100311. 10.1016/j.esmoop.2021.100311.
|
|
|
Ledermann, JA;
Embleton-Thirsk, AC;
Perren, TJ;
Jayson, GC;
Rustin, GJS;
Kaye, SB;
Hirte, H;
... ICON6 collaborators, .; + view all
(2021)
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
ESMO Open
, 6
(2)
, Article 100043. 10.1016/j.esmoop.2020.100043.
|
|
|
Lee, CK;
Friedlander, ML;
Tjokrowidjaja, A;
Ledermann, JA;
Coleman, RL;
Mirza, MR;
Matulonis, UA;
... Scott, CL; + view all
(2021)
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Cancer
, 127
(14)
pp. 2432-2441.
10.1002/cncr.33517.
|
M
|
Mandair, D;
Khan, MS;
Lopes, A;
Furtado O'Mahony, L;
Ensell, L;
Lowe, H;
Hartley, JA;
... Meyer, T; + view all
(2021)
Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
Journal of Clinical Endocrinology and Metabolism
, 106
(3)
pp. 872-882.
10.1210/clinem/dgaa822.
|
|
Martinez-Calle, N;
Kirkwood, AA;
Lamb, M;
Smith, A;
Khwaja, J;
Manos, K;
Shrubsole, C;
... Fox, CP; + view all
(2021)
Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.
Advances in Therapy
10.1007/s12325-021-01764-0.
|
|
|
McCulloch, R;
Lewis, D;
Crosbie, N;
Eyre, TA;
Bolam, S;
Arasaretnam, A;
Creasey, T;
... Rule, S; + view all
(2021)
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
British Journal of Haematology
10.1111/bjh.17363.
|
|
|
Mikhaeel, NG;
Cunningham, D;
Counsell, N;
McMillan, A;
Radford, JA;
Ardeshna, KM;
Lawrie, A;
... Barrington, SF; + view all
(2021)
FDG‐PET/CT after two cycles of R‐CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study.
British Journal of Haematology
, 192
(3)
pp. 504-513.
10.1111/bjh.16875.
|
|
Mitchell, RJ;
Kirkwood, AA;
Barretta, E;
Clifton-Hadley, L;
Lawrie, E;
Lee, S;
Leongamornlert, D;
... Fielding, AK; + view all
(2021)
IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial.
Blood Advances
, 5
(17)
pp. 3322-3332.
10.1182/bloodadvances.2021004430.
|
|
|
Monk, BJ;
Colombo, N;
Oza, AM;
Fujiwara, K;
Birrer, MJ;
Randall, L;
Poddubskaya, EV;
... Ledermann, JA; + view all
(2021)
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
The Lancet Oncology
, 22
(9)
pp. 1275-1289.
10.1016/S1470-2045(21)00342-9.
|
|
Moorman, Anthony;
Butler, Ellie;
Barretta, Emilio;
Kirkwood, Amy A;
Schwab, Claire;
Creasey, Thomas;
Leongamornlert, Daniel A;
... Enshaei, Amir; + view all
(2021)
Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.
Leukemia
10.1038/s41375-021-01448-2.
(In press).
|
|
|
Morgan, RD;
McNeish, IA;
Cook, AD;
James, EC;
Lord, R;
Dark, G;
Glasspool, RM;
... Clamp, AR; + view all
(2021)
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
The Lancet Oncology
, 22
(2)
pp. 277-288.
10.1016/S1470-2045(20)30591-X.
|
|
O
|
O'Connor, MN;
Kallenberg, DM;
Camilli, C;
Pilotti, C;
Dritsoula, A;
Jackstadt, R;
Bowers, CE;
... Greenwood, J; + view all
(2021)
LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency.
Med
, 2
(11)
1231-1252.e10.
10.1016/j.medj.2021.10.002.
|
|
Oaknin, A;
Oza, AM;
Lorusso, D;
Aghajanian, C;
Dean, A;
Colombo, N;
Weberpals, JI;
... Coleman, RL; + view all
(2021)
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
Cancer Medicine
10.1002/cam4.4260.
(In press).
|
|
P
|
Petit, C;
Lacas, B;
Pignon, J-P;
Le, QT;
Grégoire, V;
Grau, C;
Hackshaw, A;
... MACH-NC and MARCH Collaborative Groups; + view all
(2021)
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis.
Lancet Oncology
, 22
(5)
pp. 727-736.
10.1016/S1470-2045(21)00076-0.
|
|
Pinato, DJ;
Scotti, L;
Gennari, A;
Colomba-Blameble, E;
Dolly, S;
Loizidou, A;
Chester, J;
... Cortellini, A; + view all
(2021)
Determinants of enhanced vulnerability to COVID-19 in UK cancer patients: a European Study.
European Journal of Cancer
, 150
pp. 190-202.
10.1016/j.ejca.2021.03.035.
|
|
Pinato, DJ;
Tabernero, J;
Bower, M;
Scotti, L;
Patel, M;
Colomba, E;
Dolly, S;
... Iglesias, M; + view all
(2021)
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study.
The Lancet Oncology
10.1016/s1470-2045(21)00573-8.
(In press).
|
|
|
Popat, R;
Counsell, N;
De Tute, R;
De-Silva, D;
Phillips, EH;
Cavenagh, JD;
Adedayo, T;
... Yong, K; + view all
(2021)
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
British Journal of Haematology
, 193
(3)
e19-e22.
10.1111/bjh.17391.
|
|
Post, CCB;
De Boer, SM;
Powell, ME;
Mileshkin, L;
Katsaros, D;
Bessette, P;
Haie-Meder, C;
... Creutzberg, CL; + view all
(2021)
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial.
International Journal of Radiation Oncology - Biology - Physics
, 109
(4)
pp. 975-986.
10.1016/j.ijrobp.2020.10.030.
|
|
Poveda, A;
Floquet, A;
Ledermann, JA;
Asher, R;
Penson, RT;
Oza, AM;
Korach, J;
... SOLO2/ENGOT-Ov21 investigators, .; + view all
(2021)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
The Lancet Oncology
, 22
(5)
pp. 620-631.
10.1016/S1470-2045(21)00073-5.
|
|
Pujade-Lauraine, E;
Fujiwara, K;
Ledermann, JA;
Oza, AM;
Kristeleit, R;
Ray-Coquard, I-L;
Richardson, GE;
... Monk, BJ; + view all
(2021)
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
The Lancet Oncology
, 22
(7)
pp. 1034-1046.
10.1016/S1470-2045(21)00216-3.
|
|
Pujade-Lauraine, Eric;
Fujiwara, Keiichi;
Ledermann, Jonathan A;
Oza, Amit M;
Kristeleit, Rebecca;
Ray-Coquard, Isabelle-Laure;
Richardson, Gary E;
... Monk, Bradley J; + view all
(2021)
Avelumab Alone or in Combination With Chemotherapy Versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study.
Obstetrical & Gynecological Survey
, 76
(11)
pp. 673-675.
10.1097/OGX.0000000000000980.
|
Q
|
Quaife, SL;
Waller, J;
Dickson, JL;
Brain, KE;
Kurtidu, C;
McCabe, J;
Hackshaw, A;
... Janes, SM; + view all
(2021)
Psychological Targets for Lung Cancer Screening Uptake: A Prospective Longitudinal Cohort Study.
Journal of Thoracic Oncology
, 16
(12)
pp. 2016-2028.
10.1016/j.jtho.2021.07.025.
|
R
|
Rockall, AG;
Barwick, TD;
Wilson, W;
Singh, N;
Bharwani, N;
Sohaib, A;
Nobbenhuis, M;
... Study Group, M; + view all
(2021)
Diagnostic accuracy of FET-PET/CT, FDG-PET/CT and diffusion-weighted MRI in detection of nodal metastases in surgically treated endometrial and cervical carcinoma.
Clinical Cancer Research
10.1158/1078-0432.ccr-21-1834.
(In press).
|
|
|
Roddie, C;
Dias, J;
O'Reilly, MA;
Abbasian, M;
Cadinanos-Garai, A;
Vispute, K;
Bosshard-Carter, L;
... Peggs, KS; + view all
(2021)
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
Journal of Clinical Oncology
10.1200/jco.21.00917.
(In press).
|
|
|
Russell, J;
Collins, A;
Fowler, A;
Karanth, M;
Saha, C;
Docherty, S;
Padayatty, J;
... Follows, GA; + view all
(2021)
Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial.
Annals of Hematology
, 100
pp. 1049-1058.
10.1007/s00277-021-04460-9.
|
|
T
|
Taylor, A;
Sundar, SS;
Bowen, R;
Clayton, R;
Coleridge, S;
Fotopoulou, C;
Ghaem-Maghami, S;
... Morrison, J; + view all
(2021)
British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic.
International Journal of Gynecologic Cancer
10.1136/ijgc-2021-002942.
(In press).
|
|
|
Tjokrowidjaja, A;
Friedlander, M;
Lord, SJ;
Asher, R;
Rodrigues, M;
Ledermann, JA;
Matulonis, UA;
... Lee, CK; + view all
(2021)
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.
European Journal of Cancer
, 154
pp. 190-200.
10.1016/j.ejca.2021.06.024.
|
V
|
Vivekanandan, S;
Fenwick, JD;
Counsell, N;
Panakis, N;
Stuart, R;
Higgins, GS;
Hawkins, MA;
(2021)
Associations between cardiac irradiation and survival in patients with non-small cell lung cancer: Validation and new discoveries in an independent dataset.
Radiotherapy and Oncology
, 165
pp. 119-125.
10.1016/j.radonc.2021.10.016.
|
W
|
Wall, EC;
Wu, M;
Harvey, R;
Kelly, G;
Warchal, S;
Sawyer, C;
Daniels, R;
... Bauer, DL; + view all
(2021)
AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC.
The Lancet
10.1016/S0140-6736(21)01462-8.
(In press).
|
|
|
Wall, EC;
Wu, M;
Harvey, R;
Kelly, G;
Warchal, S;
Sawyer, C;
Daniels, R;
... Bauer, DLV; + view all
(2021)
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.
The Lancet
10.1016/s0140-6736(21)01290-3.
(In press).
|
|
|
Watts, C;
Ashkan, K;
Jenkinson, MD;
Price, SJ;
Santarius, T;
Matys, T;
Zhang, TT;
... Counsell, N; + view all
(2021)
An evaluation of the tolerability and feasibility of combining 5-amino-levulinic acid (5-ala) with bcnu wafers in the surgical management of primary glioblastoma.
Cancers
, 13
, Article 3241. 10.3390/cancers13133241.
|
|
|
Willis, SE;
Winkler, C;
Roudier, MP;
Baird, T;
Marco-Casanova, P;
Jones, E;
Rowe, P;
... Jones, GN; + view all
(2021)
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
British Journal of Cancer
10.1038/s41416-021-01560-1.
|
|
|
Wong, Yien Ning Sophia;
(2021)
Identification of urine derived lymphocytes as a non-invasive measure of the tumour immune microenvironment in bladder cancer.
Doctoral thesis (Ph.D), UCL (University College London).
|
|
Wong, YNS;
Sng, CCT;
Ottaviani, D;
Patel, G;
Chowdhury, A;
Earnshaw, I;
Sinclair, A;
... Lee, AJX; + view all
(2021)
Systemic anti-cancer therapy and metastatic cancer are independent mortality risk factors during two uk waves of the covid-19 pandemic at university college london hospital.
Cancers
, 13
(23)
, Article 6085. 10.3390/cancers13236085.
|
|
